// App-Quantinova.ai

8012 : Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial.

Researchers

Presenter

  • Martin F. Kaiser

Principal Investigators

  • Bhupinder Sharma

  • Daniel Levine

  • Dow-Mu Koh

  • Kevin Boyd

  • Charlotte Pawlyn

  • Angela M. Riddell

  • Kate Downey

  • Alison Bonner

  • Veronica A Morgan

  • Simon Stern

  • Lydia Jones

  • Betty Cheung

  • Charalampia Kyriakou

  • Pawel Kaczmarek

  • Jessica Mary Winfield

  • Matthew D. Blackledge

  • Wim J.G. Oyen

  • Christina Messiou

Medical Centers

  • Institute for Cancer Research, London, United Kingdom

  • Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom

  • 197 Fulham Road, London, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Royal Marsden Hospital, Surrey, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Epsom and St Helier University Hospitals NHS Trust, Epsom, United Kingdom

  • Neonatal Unit, Croydon University Hospital, London, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Surrey and Sussex NHS Healthcare Trust, Redhill, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • The Department of Radiology and Nuclear Medicine, Rijnstate, Arnhem, Netherlands

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

Locations

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • 18F-fluorodeoxyglucose

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Prospective

Phase

  • N/A

Study Id's

  • NCT02403102

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved